Impact of Sars-CoV-2 Prophylaxis with Tixagevimab-Cilgavimab in High-Risk Patients with B-Cell Malignancies: A Single-Center Retrospective Study
Mediterr J Hematol Infect Dis
.
2023 Nov 1;15(1):e2023061.
doi: 10.4084/MJHID.2023.061.
eCollection 2023.
Authors
Giovanni Manfredi Assanto
1
,
Matteo Totaro
1
,
Rebecca Poggiali
1
,
Adele Delli Paoli
1
,
Giorgia Annechini
1
,
Gianna Maria D'Elia
1
,
Francesco Aji
1
,
Luigi Petrucci
1
,
Francesca Fazio
1
,
Ilaria Del Giudice
1
,
Maurizio Martelli
1
,
Alessandra Micozzi
1
,
Giuseppe Gentile
1
Affiliation
1
Hematology, Department of Translational and Precision Medicine, Sapienza University, Rome, Italy.
PMID:
38028390
PMCID:
PMC10631717
DOI:
10.4084/MJHID.2023.061
No abstract available
Keywords:
B-Cell malignancies; COVID-19; Pre-exposure; Prophylaxis; Tixagevimab-cilgavimab.